This article explores the international legal mechanisms designed to regulate the production, distribution, and consumption of new synthetic drugs (NSDs), also known as new psychoactive substances (NPS)

Аннотация

This article explores the international legal mechanisms designed to regulate the production, distribution, and consumption of new synthetic drugs (NSDs), also known as new psychoactive substances (NPS). NSDs present unique regulatory challenges due to their rapid proliferation, structural variability, and evasion of traditional drug control laws. The article analyzes the role of key international treaties such as the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 UN Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Additionally, it critically evaluates the functioning of the United Nations Office on Drugs and Crime (UNODC), the International Narcotics Control Board (INCB), and the World Health Organization (WHO) in addressing the NSD crisis. Case studies from the European Union, the United States, and Central Asia, particularly Uzbekistan, are included to demonstrate the impact of national implementation and the gaps in legal harmonization. Recommendations for treaty reform, enhanced data-sharing, and a flexible legal approach to synthetic drug regulation are presented. Keywords: New synthetic drugs, international drug law, NPS, UNODC, INCB, WHO, Convention on Psychotropic Substances, international regulation, synthetic cannabinoids, psychoactive substances Introduction. The proliferation of new synthetic drugs (NSDs), commonly referred to as new psychoactive substances (NPS), has posed significant challenges to international drug regulation frameworks. Unlike traditional narcotics, NSDs are often not immediately scheduled under international conventions, allowing producers to exploit legal grey areas. This article aims to provide a comprehensive overview of the international legal response to NSDs, examining the strengths and weaknesses of current instruments, the roles of key stakeholders, and proposals for future improvements. Defining New Synthetic Drugs. NSDs are synthetic or semi-synthetic substances designed to mimic the effects of controlled drugs such as cannabis, ecstasy, cocaine, or LSD. These substances are often chemically altered to evade 26 ACADEMIC RESEARCH IN MODERN SCIENCE International scientific-online conference existing legal controls while retaining psychoactive properties.1 Categories include synthetic cannabinoids, cathinones, phenethylamines, and opioids. Historical Background of International Drug Control. The evolution of drug control law began with the 1912 Hague Convention and developed through the 1961 Single Convention, which consolidated prior agreements. The 1971 Convention addressed the rise of synthetic psychotropics, while the 1988 Convention sought to tackle trafficking and precursor control. Despite their comprehensiveness, these instruments struggle to adapt quickly to the NSD phenomenon. The 1961 Single Convention on Narcotic Drugs. This convention aimed to restrict drugs to medical and scientific purposes, establishing a scheduling system based on medical utility and abuse potential. However, it focused primarily on natural substances and provided limited flexibility for rapidly emerging synthetics. The 1971 Convention on Psychotropic Substances. This treaty expanded control to synthetic substances such as LSD and amphetamines, dividing them into four schedules. However, the scheduling process is lengthy and reliant on WHO scientific assessments, creating regulatory lag.2 The 1988 Convention against Illicit Traffic. This convention focused on law enforcement cooperation, criminalization of drug offenses, and control over precursor chemicals. It enabled international coordination but lacks specific mechanisms for emerging NSDs. United Nations Office on Drugs and Crime (UNODC). UNODC provides technical assistance, promotes international cooperation, and maintains the Early Warning Advisory on NSDs. However, its mandates rely heavily on member state implementation. International Narcotics Control Board (INCB). INCB monitors compliance with treaties and coordinates national data collection but has limited enforcement capacity. Its recommendations are not binding and often lag behind real-time drug trends. World Health Organization (WHO). WHO's Expert Committee on Drug Dependence (ECDD) provides scientific assessments of substances for scheduling. The process is crucial but time-consuming, impeding timely global responses. Producers of NSDs exploit the delay in listing new substances by 27 ACADEMIC RESEARCH IN MODERN SCIENCE International scientific-online conference slightly altering chemical structures. These analogues often remain legal until specifically banned. WHO’s scientific evaluation and subsequent scheduling under the 1971 Convention can take years, during which substances remain on the market. Online and dark web markets facilitate rapid international distribution. The transnational nature of these networks undermines national enforcement efforts.3 Comparative Legal Frame